

Memorandum of Understanding





Memorandum of Understanding

Between

The Organisation of European Cancer Institutes - EEIG (OEI)

And

CAC Blida Anti-Cancer Centre
Algeria

AC Camargo Cancer Center
Brazil

Instituto Oncológico Fundación Arturo López Pérez (FALP)
Chile

Cancer Center of Jinshazhou Hospital - University of Chinese Medicine Sciences of Guangzhou
China

Instituto Nacional de Cancerología – ESE
Colombia

King Hussein Cancer Center
Jordan

Naef K Basile Cancer Institute at the American University of Beirut
Lebanon

Public Health Institution Oncological Institute
Moldova

The Aga Khan Hospital, Dar es Salaam
Tanzania

National Cancer Institute
Ukraine

Viet Nam National Cancer Hospital
Viet Nam



1. Purpose and background of Memorandum of Understanding

The Parties being actively involved in the progress against cancer in Europe and worldwide, jointly agree to strengthen their relationship and to identify common grounds for collaboration and interactions in the field of education, research, care, quality and management of a cancer centre or a continental network.

2. The OECIWORLD Programme in details

The Parties agree to focus the collaboration on the below main points:

- Promote the concept of quality in their institutions
- Access, where possible, the OECD Accreditation and Designation Programme
- Define new certification models adapted to local contexts
- Create new bilateral collaborations between European and extra-European institutes
- Develop projects on international financing funds
- Collaborate in the establishment of new oncology networks that bring together specific countries on a continent tailored on the OECD model
- Support the adoption of national cancer plans
- Support the concept of patient as a recipient of the best treatment opportunities notwithstanding his/her residency
- Bring OECD and institutes from other continents closer to the WHO and IARC programmes
- Other foreseen fields of collaboration

Each Country will discuss and agree with OECD the details of the collaboration and the actions to be followed. If requested, an addendum to this MoU will be signed among the two parties involved.

3. Promotional Activities

The Parties agree to cross promote their initiatives on their respective websites, via social media and in member newsletters, as appropriate. Specifically, the Parties agree to encourage mutual participation at each other's conferences and annual meetings.

The Parties will verify the feasibility to register this MoU under the appropriate Authority of their Countries.

4. Educational Activities

The Parties will interact to agree, realise and promote educational activities in major cancer fields, verifying the feasibility to apply for grants of the European Commission and other financial instruments from international or national bodies. OECD will verify the feasibility to include the OECIWORLD training activities among the continuing education Programme of the OECD Academy.



5. Future Meetings

Each year, an OECIWORLD Network meeting shall be held in order to present the results achieved and future plans. The meeting will be hosted by a participant centre, which will be selected on a voluntary base.

6. Finances

This MoU does not involve a specific financial support from the Parties and it will be supported by voluntary investments of the Parties, donations and grants. The possibility to find an industrial sponsor is not excluded.

7. Term of the MOU

Nothing in this MoU is intended to or shall be deemed to establish an exclusive relationship between the Parties or to restrict any activities that each Party would otherwise be able to undertake. The Parties also agree that nothing in this MoU is intended to or shall be deemed to establish any joint venture among the Parties or constitute any Party as an agent of the other Parties.

This MoU takes effect upon signature by the authorised delegates of the Parties.

The term of this MoU begins upon signing of this agreement and runs to 31 December 2026. Extension of the MoU is to be agreed to in advance of the termination date and no later than six months prior to the termination date.

8. Amendment and changes


The terms of this MoU may be amended at any time by agreement in writing between the Parties.

9. Legal Framework


All disputes by the Parties, relating to the interpretation and implementation of this MOU and/or its clauses will be solved in a friendly and collegial manner directly between the authorised Parties below.

Signed in Inveruno on September 12th 2024


Organisation of European Cancer Institutes - BELGIUM
Thierry Philip on behalf of **Giovanni Apolone**




CAC Blida Anti-Cancer Centre - ALGERIA
Adda Bounedjar




AC Camargo Cancer Center - BRAZIL
Victor Piana de Andrade



Instituto Oncológico Fundación Arturo López Pérez (FALP) - CHILE
Alfredo Comandari




Cancer Center of Jinshazhou Hospital
Un. of Chinese Med. Sciences of Guangzho CHINA
Zhang Xiuping




Instituto Nacional de Cancerología – ESE - COLOMBIA
Carolina Wiesner


King Hussein Cancer Center - JORDAN
Asem Mansour




Naef K Basile Cancer Institute at the American University
of Beirut - LEBANON
Ali Taher




Public Health Institution Oncological Institute - MOLDOVA
Ruslan Baltaga



The Aga Khan Hospital, Dar es Salaam - TANZANIA
Harrison Chuwa



National Cancer Institute - UKRAINE
Anton Burlaka



Viet Nam National Cancer Hospital - VIET NAM
Dao Van Tu

